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Supporting materials   
 
Supplementary models 
Details of the individual patient data network meta-analysis models including treatment by 
covariate interactions that were applied are given below. 
 
Notation 
Let i denote the trial where           and NS is the number of independent trials; let j 
the patient where             such that     is the number of patients in trial i; and let k 
be the trial arm where            and     is the number of arms in trial i.  
 
Suppose         if patient j in trial i in arm k experiences the event and        if patient j 
in trial i in arm k does not experience the event. Assume that the outcomes of patients,     , 
are independent and distributed as                      where      is the probability of an 
event for patient j in trial i in arm k. Let      be a patient-level covariate for patient j in trial i 
in arm k (such as, a continuous covariate value or an indicator variable for a dichotomous 
covariate). 
 
Let     denote the treatment given in trial i in arm k where               
 
and NT is the 
number of treatments in the network. Also specify that the node being split is (  ,   ) where 
       and         For example, if one wants to split the node (3, 4) then      and     .  
 
Model S1. NMA model including treatment by covariate interaction  
Assuming no multi-arm trials exist, the random-effects model is given as follows: 
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where    is the log odds of an event in arm 1 of trial i;     is a study-specific regression 
parameter that represents the difference in the log odds of an event in arm 1 of trial i per unit 
increase in the covariate     ;          represents the difference in the log odds ratio of     vs. 
    per unit increase in the covariate and         =      -      ; and        represents the trial-
specific log odds ratio of     vs.    . The trial-specific log odds ratios,        are assumed to be 
realisations from a normal distribution where  
 
                   
   
 
and  
 
                       
 
In this model,          represents the log odds ratio of     vs.    . The fixed-effect model is 
given by setting       
 
Under a Bayesian framework, prior distributions are specified for   ,    ,        ,        and 
    
 
The model can also be applied to datasets with multi-arm trials but the correlation between 
trial-specific treatment effects must be taken into account. For each multi-arm trial i with m 
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arms, the trial-specific treatment effects are taken to be a realisation from a multivariate 
normal distribution 
 
 
       
 
       
     
             
 
             
   
       
   
       
   
 
that can be decomposed into a series of conditional univariate normal distributions. 
 
Model S2. NMA node-splitting model including treatment by covariate interaction 
When there are no multi-arm trials, the random-effects model is specified as follows: 
 
            
 
 
                                                                 
                                                                       
 
                     
                                                
 
         
 
and where      represents the difference in the log odds ratio of    vs.    per unit increase in 
the covariate estimated using direct evidence;           represents the difference in the log odds 
ratio of     vs.     per unit increase in the covariate estimated using all trials that did not 
allocate   and    (i.e. using indirect evidence); and        represents the trial-specific log odds 
ratio of     vs.    . The trial-specific log odds ratios,        are assumed to be realisations from 
a normal distribution where  
 
         
         
     
 if trial i allocated   and   , that is,         and      
 ; whereas 
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and the treatment effects satisfy the consistency equation                        
if trial i did not allocate   and   , that is,         and/or      
 .  
 
In this model          represents the mean log odds ratio of     vs.     when the covariate value 
is zero estimated using all studies that did not allocate    and    (i.e. using indirect evidence); 
and      represents the mean log odds ratio of           when the covariate value is zero 
estimated using direct evidence.  
 
Under a Bayesian framework, prior distributions are specified for   ,    ,        ,       ,   
   ,  
     and     
 
Multiple node-splitting models are usually applied. One model can be applied for each 
comparison providing both direct and indirect evidence are available for that comparison. 
 
Node-splitting models can accommodate multi-arm trials as described elsewhere (Dias et al., 
2010a, van Valkenhoef et al., 2016).  If one wants to split node (   ,    ) then a multi-arm trial 
i will contribute direct evidence to the treatment effect (    ) because       . However, if 
one splits another node                  then        therefore, the multi-arm trial would not 
contribute direct evidence to the estimation of the treatment effect (     ), therefore, to 
overcome this problem and to utilise all the direct evidence, if the multi-arm trial compared 
the two treatments    and   , in addition to other treatments, treatment    is taken to be the 
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baseline treatment     for that study. For example, if a trial i compared treatments 1, 3 and 4, 
and one wants to split node (1, 3) then          and the model would be as follows: 
                       for treatment 1, 
                                 
         for treatment 3 where       ~     
       , 
and  
                                          for treatment 4 where       ~          
  . 
 
Whereas, for the same trial, if one wants to split node (3, 4) instead, then we fix        
  and the model is  
                                          for treatment 1 where       ~          
  . 
                       for treatment 3, and  
                                 
         for treatment 4 where            
       . 
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Code for Model S1 
 
Winbugs code (saved as winbugs file "NMA RE IPD COVM1.odc") 
 
model{                                                                                     
for(i in 1:ns){                                                      #LOOP FOR EACH TRIAL               
    w[i,1] <- 0                                                       #W IS ZERO FOR ARM 1 OF EACH TRIAL 
    delta[i,1] <- 0                                                  #TREATMENT EFFECT IS ZERO FOR ARM 1 OF EACH TRIAL 
    mu[i] ~ dnorm(0,0.00001)                              #PRIOR DISTRIBUTION FOR MU 
    beta0[i] ~ dnorm(0,0.00001)                          #PRIOR DISTRIBUTION FOR BETA0 
        for (k in 2:na[i]) {                                       #LOOP FOR EACH ARM 
           delta[i,k] ~ dnorm(md[i,k], taud[i,k])      #DISTRIBUTION OF TRIAL-SPECIFIC TREATMENT EFFECTS 
           md[i,k] <-  d[t[i,k]] - d[t[i,1]] + sw[i,k]   #MEAN OF DISTRIBUTION (CORRECTED FOR MULTI-ARM 
TRIALS) 
           taud[i,k] <- tau *2*(k-1)/k                       #PRECISION OF DISTRIBUTION (CORRECTED FOR MULTI-ARM 
TRIALS) 
           w[i,k] <- (delta[i,k] - d[t[i,k]] + d[t[i,1]]) #ADJUSTMENTS FOR MULTI-ARM TRIALS 
           sw[i,k] <- sum(w[i,1:k-1])/(k-1)               #ADJUSTMENTS FOR MULTI-ARM TRIALS 
                             } 
                  }    
for(l in 1:np)  {                                                                                                     #LOOP FOR EACH PATIENT 
   y[l]~dbern(p[l])                                                                                                 #BERNOULLI LIKELIHOOD 
   logit(p[l])<-mu[s[l]] + (beta0[s[l]]*(x[l]-mx)) + delta[s[l],arm[l]] + (beta[tipd[l]]-beta[b[l]]) * (x[l]-mx)    
                     #LINEAR PREDICTOR                                                                                                                                                                                                       
   rhat[l] <- p[l]                                                                                                      #MODEL PREDICTION 
   dev[l] <- 2*(y[l] * (log(y[l]/rhat[l])) + (1-y[l]) * (log((1-y[l])/(1-rhat[l]))))     #DEVIANCE                                                   
                     }   
 
totresdev <- sum(dev[])                                                      #TOTAL RESIDUAL DEVIANCE 
                    
d[1]<-0                                                                               #LOG ODDS RATIO IS ZERO FOR REFERENT TREATMENT 
beta[1] <- 0                                                                         #COEFFICIENT IS ZERO FOR REFERENT TREATMENT 
 
sd ~ dunif(0,10)                                                                 #PRIOR DISTRIBUTION FOR BETWEEN TRIAL STANDARD  
             DEVIATION 
tau <- pow(sd,-2)                                                               #BETWEEN TRIAL PRECISION  
tausq <- sd*sd                                                                    #BETWEEN TRIAL VARIANCE 
 
for (k in 2:nt){                                   
    d[k] ~ dnorm(0,0.00001)                                                #PRIOR DISTRIBUTIONS  
    beta[k]~dnorm(0,0.00001)                                               
                     } 
 
for (k in 1:nt){                                                                  #CALCULATE THE LOG ODDS RATIO FOR BASIC  
                 PARAMETERS AT EACH COVARIATE VALUE 
    for (j in 1:nz) {                                                               
        dz[j,k] <- d[k] - (beta[k])*(mx-z[j]) }                        
                          } 
 
for (c in 1:(nt-1)){                                                             #CALCULATE, FOR EACH COMPARISON, THE 
            COEFFICIENT, ODDS RATIO AND LOG ODDS RATIO AT    
             MEAN COVARIATE VALUE. 
     for (k in (c+1):nt)  {                                                      
             betas[c,k] <- beta[k] - beta[c]                                
             or[c,k] <- exp(d[k] - d[c])                                     
             lor[c,k] <- (d[k]-d[c])                                            
                 for (j in 1:nz) { 
          #CALCULATE, FOR EACH COMPARISON, ODDS RATIO AND   
            LOG ODDS RATIO AT DIFFERENT COVARIATE VALUES 
                     orz[j,c,k] <- exp(dz[j,k] - dz[j,c]) 
                     lorz[j,c,k] <- (dz[j,k]-dz[j,c]) 
                                      } 
                                 }   
                          } 
} 
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Dataset 1 (saved a csv file"utf_ipdacc.csv") 
#t1= treatment in arm 1, t2=treatment in arm 2, t3=treatment in arm 3. 
#na=number of arms 
#Note that each row represents one study and the studies are in the same order as in dataset 2.  
 
t1 t2 t3 na 
1 2 NA 2 
1 2 NA 2 
1 2 3 3 
1 2 3 3 
1 2 3 3 
1 2 3 3 
1 2 3 3 
1 2 4 3 
1 2 4 3 
1 3 NA 2 
1 3 NA 2 
1 3 NA 2 
1 3 NA 2 
1 3 4 3 
1 3 4 3 
1 3 4 3 
1 3 4 3 
 
Dataset 2 (saved as csv file "utf_ipdacc2.csv") 
(one row per patient)  
#age=covariate 
#y=binary IPD outcome 
#tipd=treatment  
#s=study 
#b=baseline treatment in that study 
#arm=study arm (i.e. 1, 2, 3) 
#note that arm 1 of each study is the baseline treatment for that study.  
 
age y tipd s b arm 
21 1 1 1 1 1 
29 1 1 1 1 1 
. . . . . . 
. . . . . . 
 
R code  
#INSTALL R PACKAGES 
library(R2WinBUGS)                              
library(coda) 
 
#CHOOSE WORKING DIRECTORY 
working.directory="c:\\dir" 
setwd(working.directory) 
 
#IMPORT DATA 
dat1 = read.csv("utf_ipdacc.csv") 
dat2 = read.csv("utf_ipdacc2.csv") 
 
#DEFINE VARIABLES THAT NEED TO BE ENTERED INTO THE WINBUGS MODEL 
na=dat1$na                                                                     #NUMBER OF ARMS IN EACH STUDY 
t=cbind(dat1$t1,dat1$t2,dat1$t3, deparse.level = 0)     #TREATMENT NUMBER  
s=dat2$s                                                                         #STUDY NUMBER 
y=dat2$y                                                                        #OUTCOME 
arm=dat2$arm                                                               #STUDYARM 
x=dat2$age/12                                                               #COVARIATE VALUES 
b=dat2$b                                                                        #BASELINE TREATMENT 
tipd=dat2$tipd                                                                #TREATMENT (IPD VERSION) 
mx=mean(x)                                                                   #AVERAGE COVARIATE VALUE 
z=c(1,2,3,4,5, mx,0)                                                       #CHOSEN COVARIATE VALUES AT WHICH TREATMENT 
EFFECTS  ARE REQUIRED TO BE ESTIMATED 
nz=length(z)                                                                   #NUMBER OF CHOSEN COVARIATE VALUES 
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ns=max(s)                                                                      #NUMBER OF TRIALS 
nt=max(tipd)           #NUMBER OF TREATMENTS 
np=length(y)           #NUMBER OF PATIENTS 
 
#LIST DATA FOR ENTRY INTO WINBUGS 
data= list("y", "s","arm", "tipd", "b", "x", "z", "mx", "t", "na", "ns","nt", "np", "nz") 
 
#DEFINE INITIAL VALUES FOR ENTRY INTO WINBUGS 
inits1 = list(d=c(NA,0,0,0), sd=1, mu=c(0,0,0,0,0,  0,0,0,0,0,  0,0,0,0,0,  0,0), beta0=c(0,0,0,0,0,  0,0,0,0,0,  0,0,0,0,0,  0,0), 
beta=c(NA,0,0,0)) 
 
#WINBUGS MODEL 
Models1 = bugs (data, inits1, model.file= "NMA RE IPD COVM1.odc",  
parameters.to.save= c("mu", "d",  "totresdev", "or", "lor", "sd", "tausq", "dz", "betas", "beta", "orz", "lorz", "beta0"), 
n.chains=1, n.iter=300000, n.burnin=100000, n.thin=5,codaPkg=FALSE, bugs.directory="c:/Program Files/WinBUGS14/",  
working.directory=working.directory) 
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Code for model S2 
 
Winbugs code (saved as winbugs file "NMA RE IPD DSPLIT BETASPLIT.odc") 
 
model{ 
for(i in 1:ns){                                                      #LOOP FOR EACH TRIAL               
    w[i,1] <- 0                                                       #W IS ZERO FOR ARM 1 OF EACH TRIAL 
       j[i,1] <-0                                                       #J IS ZERO FOR ARM 1 OF EACH TRIAL 
      delta[i,bi[i]] <- 0                                            #TREATMENT EFFECT IS ZERO FOR ARM 1 OF EACH TRIAL 
    mu[i] ~ dnorm(0,0.00001)                              #PRIOR DISTRIBUTION FOR MU 
    beta0[i] ~ dnorm(0,0.00001)                           #PRIOR DISTRIBUTION FOR BETA0 
 for (k in 1:na[i]) {                                #LOOP FOR EACH ARM 
      index[i,k] <- split[i] * (equals(t[i,k], pair[1]) + equals(t[i,k], pair[2]))  #INDICATES IF ARM IS TO BE SPLIT 
         } 
           for (k in 2:na[i]) { 
                 delta[i,si[i,k]] ~ dnorm(md[i,si[i,k]],taud[i,si[i,k]])                                    #DISTRIBUTION OF TRIAL- 
      SPECIFIC TREATMENT EFFECTS 
                 md[i,si[i,k]] <-  (d[si[i,k]] - d[bi[i]] + sw[i,k])*(1-index[i,m[i,k]]) + direct*index[i,m[i,k]]     
      #MEAN OF DISTRIBUTION      
       (CORRECTED FOR MULTI-ARM  
       TRIALS) SPLIT INTO DIRECT AND  
       INDIRECT 
     j[i,k] <- k - (equals(1, split[i]) * step(k-3)) 
                 taud[i,si[i,k]] <- tau *2*(j[i,k]-1)/j[i,k]                                                       #PRECISION OF DISTRIBUTION  
      (CORRECTED FOR MULTI-ARM  
      TRIALS) 
                 w[i,k] <- (delta[i,si[i,k]]  - d[si[i,k]] + d[bi[i]]) * (1-index[i,k])                 #ADJUSTMENTS FOR MULTI-ARM  
       TRIALS 
                 sw[i,k] <- sum(w[i,1:k-1])/(j[i,k]-1)                                                            #ADJUSTMENTS FOR MULTI-ARM  
      TRIALS 
                 }           
                    } 
 
for(l in 1:np)  {                                                                                                             #LOOP FOR EACH PATIENT 
   y[l]~dbern(p[l])                                                                                                        #BERNOULLI LIKELIHOOD 
       logit(p[l])<-mu[s[l]]  +  beta0[s[l]]*(x[l]-mx)  +  delta[s[l], tipd[l]] + (deltab[l]*(1-equals(tipd[l],bi[s[l]])) )  
                      #LINEAR PREDICTOR     
   rhat[l] <- p[l]                                                                                                             #MODEL PREDICTION 
   dev[l] <- 2*(y[l] * (log(y[l]/rhat[l])) + (1-y[l]) * (log((1-y[l])/(1-rhat[l]))))            #DEVIANCE                                                   
       index2[l] < - split[s[l]] *  (equals(tipd[l], pair[1]) + equals(tipd[l], pair[2]))       #INDICATES IF ARM IS TO BE SPLIT 
       deltab[l] <-  (beta[tipd[l]] - beta[bi[s[l]]] )*(x[l]-mx)*(1-index2[l]) + directbeta*(x[l]-mx)*(index2[l])   
      #TREATMENT BY COVARIATE  
        INTERACTION TERM SPLIT INTO    
        DIRECT AND INDIRECT    
                     }   
  
totresdev <- sum(dev[])                                                      #TOTAL RESIDUAL DEVIANCE 
 
direct ~ dnorm(0,0.00001)                              #PRIOR DISTRIBUTION OF LOG ODDS RATIO FROM  
             DIRECT EVIDENCE 
directbeta ~ dnorm(0,0.00001)                                           #PRIOR DISTRIBUTION OF COEFFICIENT FROM DIRECT  
              EVIDENCE  
d[1]<-0                                                                               #LOG ODDS RATIO IS ZERO FOR REFERENT TREATMENT 
beta[1] <- 0                                                                         #COEFFICIENT IS ZERO FOR REFERENT TREATMENT 
 
sd ~ dunif(0,10)                                                                 #PRIOR DISTRBIUTION FOR BETWEEN TRIAL STANDARD  
             DEVIATION 
tau <- pow(sd,-2)                                                               #BETWEEN TRIAL PRECISION  
tausq <- sd*sd                                                                    #BETWEEN TRIAL VARIANCE 
 
for (k in 2:nt){                                   
    d[k] ~ dnorm(0,0.00001)                                                #PRIOR DISTRIBUTIONS FOR LOG ODDS RATIO  AND  
              COEFFICIENT FROM INDIRECT EVIDENCE 
    beta[k]~dnorm(0,0.00001)                                               
                     } 
   
for (k in 1:nt){                                                                  #CALCULATE THE LOG ODDS RATIO FOR BASIC  
 10 
 
PARAMETERS AT EACH COVARIATE VALUE FOR             
INDIRECT EVIDENCE 
 
       for (v in 1:nz) { dz[v,k] <- d[k] - (beta[k])*(mx-z[v]) } 
                     } 
 
for (c in 1:(nt-1)){                                                             #CALCULATE, FOR EACH COMPARISON, THE 
            COEFFICIENT, ODDS RATIO AND LOG ODDS RATIO AT    
             MEAN COVARIATE VALUE FOR INDIRECT EVIDENCE. 
     for (k in (c+1):nt)  {                                                      
             betas[c,k] <- beta[k] - beta[c]                                
             lor[c,k] <- (d[k]-d[c])                                            
                         for (v in 1:nz) { 
          #CALCULATE, FOR EACH COMPARISON, ODDS RATIO AND   
            LOG ODDS RATIO AT DIFFERENT COVARIATE VALUES 
                            FOR INDIRECT EVIDENCE.  
            lorz[v,c,k] <- (dz[v,k]-dz[v,c]) 
                                        } 
                               }   
                     }      
 
for (v in 1:nz) {                                                             #LOG ODDS RATIO  AND ODDS RATIO AT EACH  
                                                                                             COVARIATE VALUE FOR DIRECT EVIDENCE. 
 
         directz[v] <- direct - (directbeta)*(mx-z[v])   
         directorz[v] <-exp(directz[v])    
                     } 
 
for (v in 1:nz) {  
        diff[v] <- directz[v] - lorz[v, pair[1], pair[2]]             #CALCULATE INCONSISTENCY ESTIMATES 
        prob[v] <- step(diff[v])                                               #CALCULATE P-VALUES 
                       } 
} 
 
R code  
#INSTALL R PACKAGES 
library(R2WinBUGS)                              
library(coda) 
 
#CHOOSE WORKING DIRECTORY 
working.directory="c:\\dir" 
setwd(working.directory) 
 
#LOAD FUNCTIONS TO SHAPE DATA   
 
#CHECK IF PAIR(X,Y) IN ROW I OF DATA AND GIVE BASELINE FOR DATA ROW I 
PairXY <- function(treat, pair) 
{ 
  N <- nrow(treat) 
  out <- cbind(split=rep(0,N), b=rep(0,N)) 
  for (i in 1:N) { 
   pos <- match(pair, treat[i,], nomatch=0)   # lenght = length(pair) = 2 
   out[i,1] <- ifelse(prod(pos)>0, 1, 0)      # 1 if pair in line i, 0 o.w. 
   out[i,2] <- ifelse(prod(pos)==0, 1, pos[1]) 
 } 
out 
} 
 
# GIVES NA-1 INDEXES TO SWEEP NON-BASELINE ARMS ONLY 
NonbaseSweep <- function(index, na) 
{ 
  N <- NROW(na) 
  C <- max(na) 
  out <- matrix(nrow=N, ncol=C) 
  for (i in 1:N) { 
   for (k in 2:na[i]) { 
     out[i,k] <- k - (index[i,"b"] >= k) 
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   } 
  } 
out 
} 
 
# BUILDS MATRIX WITH NON-BASELINE TREATMENTS 
Sweeptreat <- function(treat, m) 
{ 
  N <- NROW(treat) 
  C <- NCOL(m) 
  out <- matrix(nrow=N, ncol=C) 
  for (i in 1:N) { 
   for (k in 2:C) { 
     out[i,k] <- treat[i,m[i,k]] 
   } 
  } 
out 
} 
 
## BUILDS VECTOR WITH BASELINE TREATMENTS 
Basetreat <- function(treat, b) 
{ 
  N <- nrow(treat) 
  out <- rep(0,N) 
  for (i in 1:N) { 
   out[i] <- treat[i,b[i]] 
  } 
out 
} 
 
#IMPORT DATA 
dat1 = read.csv("utf_ipdacc.csv") 
dat2 = read.csv("utf_ipdacc2.csv") 
 
#DEFINE VARIABLES THAT NEED TO BE ENTERED INTO THE WINBUGS MODEL 
na=dat1$na                                                                     #NUMBER OF ARMS IN EACH STUDY 
t=cbind(dat1$t1,dat1$t2,dat1$t3, deparse.level = 0)     #TREATMENT NUMBER  
s=dat2$s                                                                         #STUDY NUMBER 
y=dat2$y                                                                        #OUTCOME 
tipd=dat2$tipd                                                                #TREATMENT NUMBER 
x=dat2$age/12                                                               #COVARIATE VALUES 
ns=max(s)                                                                      #NMUBER OF TRIALS 
nt=max(tipd)           #NUMBER OF TREATMENTS 
np=length(y)           #NUMBER OF PATIENTS 
mx=mean(x)                                                                   #AVERAGE COVARIATE VALUE 
z=c(1,2,3,4,5, mx,0)                                                       #CHOSEN COVARIATE VALUES AT WHICH TREATMENT 
EFFECTS  ARE REQUIRED TO BE ESTIMATED. 
nz=length(z)                                                                  #NUMBER OF CHOSEN COVARIATE VALUES 
 
#DEFINE INITIAL VALUES FOR ENTRY INTO WINBUGS 
inits1 = list(direct=0, d=c(NA,0,0,0), mu=rep(0,ns), directbeta=0, beta0=c(0,0,0,0,0,  0,0,0,0,0,  0,0,0,0,0,  0,0), 
beta=c(NA,0,0,0), beta=c(NA,0,0,0), sd=1) 
 
#CHOOSE NODE TO SPLIT 
pair <- c(2,3) 
 
# CALCULATE SPLIT (=1 IF NODE TO SPLIT IS PRESENT AND 0 OTHERWISE)  
checkPair <- PairXY(t, pair) 
 
# BUILD VECTOR BI[I] WITH BASELINE TREATMENT: T[I, B[I]] 
bi <- Basetreat(t, checkPair[,"b"]) 
 
# INDEXES TO SWEEP NON-BASELINE ARMS ONLY 
m <- NonbaseSweep(checkPair, na) 
 
# BUILD MATRIX SI[I,K] WITH NON-BASELINE TREATMENTS: T[I, M[I,K]] 
si <- Sweeptreat(t,m) 
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#LIST DATA FOR ENTRY INTO WINBUGS 
bugs.data(list("y"=y,"s"=s,"tipd"=tipd, 
               "na" = na, "nt" = nt, "ns" = ns,"np" = np, "t"=t, 
               "split" = checkPair[,"split"], "m" =m, 
               "bi" = bi, "si" = si, "pair" = pair, "x"=x, "z"=z, "nz"=nz,"mx"=mx ) ) 
 
#WINBUGS MODEL 
modelS2=bugs(data = "data.txt", 
     inits = inits1, parameters.to.save = c("direct", "d", "lor", "mu", "prob","totresdev", "diff", "directbeta", "directz", "lorz", 
"betas", "dz","beta", "sd", "tausq"), model.file = "NMA RE IPD DSPLIT BETASPLIT.odc", 
     n.chains = 1,  n.iter = 300000, n.burnin = 100000,  bugs.directory = "C:/Program Files/WinBUGS14/", 
working.directory=working.directory) 
 
######REPEAT FOR OTHER NODES
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Site Artemisinin-based combination therapies  
 (number of patients that achieved treatment success/number of patients) 
Age in years, mean  
(standard deviation) 
DHAPQ AQ+AS AL CD+A 
Manhica (after CD+A) 94/100 78/97 - - 2.88 (1.30) 
Mbarara (after CD+A) 63/65 59/70 - - 2.43 (1.07) 
Nanoro 187/219 199/290 115/292 - 2.24 (1.18) 
Gabon 62/63 67/76 65/70 - 2.83 (1.28) 
Afokang 67/72 78/83 84/87 - 2.94 (1.28) 
Pamol 60/65 73/79 73/80 - 2.66 (1.36) 
Ndola 67/67 63/69 63/75 - 2.45 (1.20) 
Manhica (before CD+A) 78/82 70/86 - 42/84 2.82 (1,00) 
Mbarara (before CD+A) 72/80 64/79 - 53/80 2.60 (1.10) 
Rukara (after CD+A) 46/47 - 46/50 - 3.08 (0.92) 
Jinja (after CD+A) 160/167 - 157/168 - 2.33 (1.17) 
Tororo (after CD+A) 54/75 - 33/77 - 1.99 (0.99) 
Mashesha (after CD+A) 49/52 - 51/52 - 2.90 (1.05) 
Rukara (before CD+A) 22/23 - 18/21 4/23 2.71 (1.00) 
Jinja (before CD+A) 37/39 - 35/38 34/40 2.62 (1.19) 
Tororo (before CD+A) 109/141 - 88/138 71/142 2.11 (0.85) 
Mashesha (before CD+A) 23/24 - 23/23 18/24 2.92 (1.09) 
Table S1. Summary of the individual patient data (i.e. event rate of each treatment group of each site for treatment success at day 28) 
and covariate information. 
AQ+AS: amodiaquine-artesunate; AL: artemether-lumefantrine; CD+A: chlorproguanil-dapsone plus artesunate; DHAPQ: dihydroartemisinin-
piperaquine. 
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Comparison Evidence type Odds ratio  
Posterior median (posterior 95% credibility interval) 
Age 1 Age 2 Mean age  
i.e. 2.5  
Age 3 Age 4 Age 5 
AL vs. AQ+AS Direct 0.65  
(0.26, 1.76) 
0.71  
(0.29, 1.81) 
0.74  
(0.31, 1.87) 
0.77  
(0.31, 1.96) 
0.83  
(0.32, 2.26) 
0.90  
(0.31, 2.72) 
Indirect 2.65  
(0.86, 9.44) 
1.89  
(0.72, 5.88) 
1.60  
(0.61, 4.90) 
1.36  
(0.50, 4.26) 
0.98  
(0.29, 3.58) 
0.71  
(0.15, 3.37) 
CD+A vs. AQ+AS Direct 0.66  
(0.13, 3.47) 
0.43  
(0.10, 1.92) 
0.34  
(0.08, 1.50) 
0.28  
(0.06, 1.21) 
0.18  
(0.04, 0.87) 
0.11  
(0.02, 0.70) 
Indirect 0.26  
(0.06, 1.02) 
0.23  
(0.06, 0.80) 
0.22  
(0.06, 0.75) 
0.21  
(0.06, 0.75) 
0.19  
(0.04, 0.83) 
0.17  
(0.03, 1.01) 
CD+A vs. AL Direct 0.24  
(0.06, 0.82) 
0.21  
(0.06, 0.62) 
0.20  
(0.06, 0.58) 
0.18  
(0.05, 0.56) 
0.16  
(0.04, 0.59) 
0.14  
(0.03, 0.70) 
Indirect 0.69  
(0.13, 3.25) 
0.43  
(0.10, 1.68) 
0.34  
(0.08, 1.30) 
0.26  
(0.06, 1.04) 
0.16  
(0.03, 0.75) 
0.10  
(0.02, 0.62) 
Table S2. Odds ratios for treatment success from the NMA node-splitting models including interactions (model S2). 
AQ+AS: amodiaquine-artesunate; AL: artemether-lumefantrine; CD+A: chlorproguanil-dapsone plus artesunate; DHAPQ: dihydroartemisinin-
piperaquine. 
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Comparison Log odds ratio  
Posterior median (posterior 95% credibility interval) 
Age 1 Age 2 Mean age  
i.e. 2.5  
Age 3 Age 4 Age 5 
AL vs. AQ+AS 0.05 
(-0.74, 0.92) 
0.05 
(-0.67, 0.87) 
0.06 
(-0.67, 0.87) 
0.06 
-0.68, 0.88 
0.07 
-0.75, 0.94 
0.08 
-0.86, 1.05 
CD+A vs. 
AQ+AS 
-0.93 
(-2.02, 0.11) 
-1.20 
(-2.18, -0.27) 
-1.34 
(-2.30, -0.42) 
-1.47 
-2.45, -0.54 
-1.74 
-2.83, -0.70 
-2.02 
-3.30, -0.77 
CD+A vs. AL -0.98 
(-2.07, -0.01) 
-1.25 
(-2.24, -0.41) 
-1.39 
(-2.36, -0.56) 
-1.53 
-2.51, -0.68 
-1.82 
-2.89, -0.82 
-2.10 
-3.37, -0.88 
Table S3. Selected results for treatment success from the NMA model including interactions (model S1). 
AQ+AS: amodiaquine-artesunate; AL: artemether-lumefantrine; CD+A: chlorproguanil-dapsone plus artesunate; DHAPQ: dihydroartemisinin-
piperaquine. The between trial variance was 0.77 (0.27, 2.07). 
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Figure S1. Posterior distributions of log odds ratios at various ages for treatment success for CD+A versus AQ+AS. 
The mean age was 2.5 years.  
AQ+AS: amodiaquine-artesunate; CD+A: chlorproguanil-dapsone plus artesunate. 
Posterior median (95% credibility interval) presented. 
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Figure S2. Posterior distributions of log odds ratios at various ages for treatment success for CD+A versus AL. 
The mean age was 2.5 years.  
AL: artemether-lumefantrine; CD+A: chlorproguanil-dapsone plus artesunate. 
Posterior median (95% credibility interval) presented. 
